Your session is about to expire
← Back to Search
Tissue Engineering
Tissue Engineered Vascular Grafts for Heart Disease (TEVG-2 Trial)
Phase 2
Recruiting
Led By Mark Galantowicz, MD
Research Sponsored by Nationwide Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient must be a candidate to undergo an extracardiac total cavopulmonary connection.
Must not have
Patient has abnormal venous drainage (interrupted inferior vena cava [IVC]).
Patient has an urgent/emergent operative status.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new type of surgery for people with heart problems. The new surgery is called "extracardiac total cavopulmonary connection." This trial is testing to see if the new surgery is safe and if it works well.
Who is the study for?
This trial is for children with certain heart defects who need a special surgery called extracardiac total cavopulmonary connection. They must be able to follow the study plan and not have urgent medical issues, pacemakers, severe heart valve problems, other serious health conditions, or need graft sizes outside of 12-24 mm. Kids with high lung blood pressure or abnormal veins can't join.
What is being tested?
The study tests second-generation tissue engineered vascular grafts (TEVG) in kids needing heart surgery to connect large veins to their lungs. It's checking if these new grafts are safe and work well over two years without using different treatment groups.
What are the potential side effects?
While specific side effects aren't listed here, TEVGs could potentially cause complications like infection, improper healing at the site where they're placed, clotting inside the graft, or an immune reaction against the graft material.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am eligible for a specific heart surgery to improve blood flow.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My veins that return blood to my heart are not normal.
Select...
I need surgery urgently or as an emergency.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and Tolerability of TEVG
Secondary study objectives
Efficacy of TEVG
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tissue Engineered Vascular GraftsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tissue Engineered Vascular Grafts
2009
Completed Phase 1
~10
Find a Location
Who is running the clinical trial?
Nationwide Children's HospitalLead Sponsor
348 Previous Clinical Trials
5,228,045 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,817 Previous Clinical Trials
8,161,735 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,935 Previous Clinical Trials
47,792,307 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You need a graft that is not between 12 and 24 millimeters in diameter.I have kidney problems as determined by my doctor.My heart valve leakage is severe, making me ineligible.Your blood vessels in the lungs have high resistance.I am not on medications like bisphosphonates that could affect the trial.I am eligible for a specific heart surgery to improve blood flow.My veins that return blood to my heart are not normal.I need surgery urgently or as an emergency.Your hemoglobin levels are less than 11.0 mg/dL before surgery.
Research Study Groups:
This trial has the following groups:- Group 1: Tissue Engineered Vascular Grafts
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger